百本醫護(02293.HK)中期純利升69.95%至3349.3萬港元
格隆匯2月22日丨百本醫護(02293.HK)公佈,截至2021年12月31日止六個月,客户合約收益為7303.6萬港元,同比增長95.16%;公司權益持有人應占溢利為3349.3萬港元,同比增長69.95%,每股盈利為8.37港仙。
期內提供醫護人手解決方案服務所得的收益約為5220萬港元,較去年同期的3540萬港元增加約1680萬港元或47.5%,主要由於新型冠狀病毒(COVID-19)檢測機構的需求所致。
期內來自提供外展個案評估相關服務的收益增長約1880萬港元至約2080萬港元,主要可歸因於對醫療及健康評估服務(尤其是香港的社區疫苗接種中心)的需求增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.